Browsing NTNU Open by Author "Vangsted, Annette Juul"

Now showing items 1-2 of 2

    • Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group 

      Gregersen, Henrik; Peceliunas, Valdas; Remes, Kari; Schjesvold, Fredrik Hellem; Abildgaard, Niels; Nahi, Hareth; Andersen, Niels Frost; Vangsted, Annette Juul; Klausen, Tobias Wirenfeldt; Helleberg, Carsten; Carlson, Kristina; Frølund, Ulf Christian; Axelsson, Per; Stromberg, Olga; Blimark, Cecilie Hveding; Crafoord, Jacob; Tsykunova, Galina; Eshoj, Henrik Rode; Waage, Anders; Hansson, Markus; Gulbrandsen, Nina (Peer reviewed; Journal article, 2021)
      Objective We investigated the efficacy and safety of carfilzomib-containing induction before salvage high-dose melphalan with autologous stem-cell transplantation (salvage ASCT) and maintenance with carfilzomib and ...

    • Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma 

      Lund, Johan; Gruber, Astrid; Lauri, Birgitta; Duru, Adil Doganay; Blimark, Cecilie; Swedin, Agneta; Hansson, Markus; Forsberg, Karin; Ahlberg, Lucia; Carlsson, Conny; Waage, Anders; Gimsing, Peter; Vangsted, Annette Juul; Frølund, Ulf; Holmberg, Erik; Gahrton, Gösta C.A.; Alici, Evren; Hardling, Mats; Mellqvist, Ulf-Henrik; Nahi, Hareth (Journal article; Peer reviewed, 2018)
      Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that single‐agent Len may be effective as prolonged treatment regimen in RRMM once ...